The investments of the pharmaceutical industry in Finland grew to EUR 357 million

The investments grew for the second year in a row. The most significant part of the investments continues to go to research and product development (€234 million) although the R&D investments decreased by 9% from the previous year. The investments in production amounted to EUR 121 million (+ 80%).

A significant proportion of the R&D investments comes from clinical trials. Studies on anticancer medicines and neurological medicines are the most studied in Finland. However, there was a slight decrease in the number of research during 2021 which is also reflected in the decrease in the research investments. 

However, many of the companies which answered to the survey expect to increase investments in Finland at least to some extent in the up coming years. The growth is estimated to be about EUR 120 million in the next couple of years.

The results of PIF’s investment survey can be found here.